Cat. No.: DAB-0012839
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human SIK2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SIK2 |
| UniProt No. | Q9H0K1 |
| Gene ID | 23235 |
| Gene Description | Salt-inducible kinase 1 was originally identified as a serine/threonine kinase from adrenocortical tissues of rats on a high salt diet. SIK1 is a SNF1/AMPK family kinase capable of autophosphorylation. SIK2 is an isoform of SIK1 and is specifically expressed in adipose tissues where it is induced during adipocyte differentiation. Studies suggest that SIK2 can phosphorylate human insulin receptor substrate at Ser794. Along with evidence that SIK2 expression and activity are increased in white adipocytes of diabetic mice, this finding suggests a possible role for SIK2 in regulating insulin signaling in adipocytes and in the development of insulin resistance. Insulin triggers Akt2-mediated phosphorylation of SIK2 at Ser358 and the resultant kinase activation during post-fasting feeding. The activated SIK2 then induces the phosphorylation of Torc2 at Ser171 resulting in translocation of this transcriptional coactivator from the nucleus to cytoplasm where it is degraded through the ubiquitin pathway, leading to inhibition of gluconeogenic gene expression. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
